We recently published a list of 10 Small–Cap Stocks Insiders Are Selling Recently. In this article, we are going to take a look at where Enfusion, Inc. (NYSE:ENFN) stands against other small–cap stocks insiders are selling recently.
Why are some investors focusing on stocks with smaller market capitalizations? Among some of the reasons are diversification of their portfolios, because small-cap stocks usually operate in different industries than large-cap companies. Another reason is the share price, which is often lower than that of companies with larger market capitalization (above $10 billion), making them more affordable.
Some investors’ strategy is finding nascent companies with strong growth potential, which can bring high returns once the companies have grown. Even though small-cap stocks often carry higher risks and are more prone to market volatility, they also offer investors more room for growth.
What are some ways to assess small-cap stocks that are worth investing in? While there’s no single simple or complicated rule that investors can follow to achieve secure results, some strategies can help. One strategy is to keep track of insider trading activity. Insiders or, in other words, people in high positions within companies, such as CEOs, CFOs, directors and other executives have valuable insights into the company’s strategic moves, plans, and initiatives. A CEO’s investment in a company’s stock can sometimes signal strong confidence in the company’s future.
Does this mean that it is a bad sign for the company when insiders sell their shares? Not necessarily; just like insider buying activity doesn’t always mean stock is heading for growth. When insiders are selling their shares, it can sometimes mean that the management is losing confidence. On the other hand, it also happens that large shareholders just want to trim their holdings to more appropriate position sizes based on the risk/reward. Insiders can also decide to sell their shares due to personal financial reasons that have nothing to do with the company.
While both insider selling and buying can be driven by various motives, it’s important to consider these moves within the broader context of the company’s fundamentals, industry trends, and overall market conditions.
To identify the 10 large-cap stocks insiders are selling recently, we considered only stocks with a market capitalization of between $250 million to $2 billion. We first used Insider Monkey’s insider trading stock screener and looked for stocks with at least two insiders selling over the last two months.
With each stock we note the number of recent insider sales and the company’s current market capitalization. But why is it important to follow insider activity? Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
A senior financial executive in a power suit in front of a modern high rise building.
Enfusion, Inc. (NYSE:ENFN)
Number of insiders selling: 6
Market capitalization: $1.063B
Enfusion, Inc. (NYSE:ENFN) is a provider of software-as-a-service solution services with a focus on the investment management industry. It simplifies investment management operations by connecting front, middle and back-office functions under one cloud-native SaaD platform. The Chicago, Illinois-headquartered fintech company offers several professional tools such as Portfolio Management System and Order and Execution Management System.
Over the past two months, six insiders, among which are the company CEO, and CFO, sold around $372,671 worth of Enfusion shares at an average price of $10.26 per share. Since the beginning of the year, the stock gained 7.57% and is now trading at $11.08 per share.
As many as five of these insider sales happened on January 7, just six days before Enfusion (NYSE:ENFN) announced it has signed an agreement to be acquired by Clearwater Analytics (NYSE:CWAN) in a deal worth approximately $1.5 billion. This could indicate that several insiders might have decided to sell their shares before the sale of the company. Why? There can be uncertainties about the acquisition deal and concerns about the future’s prospects. Or, some investors might have sold their shares out of fear the price might drop after the acquisition.
How do analysts feel about the deal? In January, Morgan Stanley (NYSE:MS) downgraded the rating on Enfusion stock from “Overweight: to “Equal-weight, and also raised the price target to $11.25 from $11.00. The downgrade came in response to the announced acquisition, writes Investing.
According to data from StockAnalysis, five analysts have an average “Hold” rating on Enfusion stock, and the 12-month price target is set to $10.38.
On the other hand, eight analysts have an average “Buy” rating on Clearwater stock and the 12-month price target is $31.75. Clearwater shares are currently trading at $27.51 per share.
Overall, ENFN ranks 10th on our list of small–cap stocks insiders are selling recently. While we acknowledge the potential of ENFN, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ENFN but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap
Disclosure: None. This article is originally published at Insider Monkey.
